- Home
- CZNC vs SIGA Comparison
CZNC vs SIGA Comparison
Compare CZNC & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | SIGA |
|---|---|---|
| Founded | 1864 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 360.7M | 401.0M |
| IPO Year | 2009 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CZNC | SIGA |
|---|---|---|
| Price | $21.73 | $5.26 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $23.50 | N/A |
| AVG Volume (30 Days) | 40.5K | ★ 475.0K |
| Earning Date | 04-29-2026 | 06-15-2026 |
| Dividend Yield | 5.17% | ★ 10.97% |
| EPS Growth | ★ 7.64 | N/A |
| EPS | ★ 1.22 | 0.32 |
| Revenue | N/A | N/A |
| Revenue This Year | $3.11 | N/A |
| Revenue Next Year | N/A | $132.36 |
| P/E Ratio | $17.76 | ★ $17.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.02 | $4.95 |
| 52 Week High | $24.12 | $9.62 |
Technical Indicators
Market Signals| Indicator | CZNC | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 37.32 | 25.09 |
| Support Level | $19.82 | $5.21 |
| Resistance Level | $22.45 | $6.98 |
| Average True Range (ATR) | 0.59 | 0.26 |
| MACD | -0.21 | -0.13 |
| Stochastic Oscillator | 17.31 | 5.31 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.